Skip to contentI
IGC Pharma, Inc.
I
IGCIGC Pharma, Inc. Q2 2020 · 10-Q
Revenue$1.82M$1.82M+124.5% vs Q2 2019 Net Income-$1.18M-$1.18MN/M vs Q2 2019 EPS Diluted-$0.03-$0.03N/M vs Q2 2019 Gross Profit$28,000+55.6% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
IGC Pharma, Inc. · CIK 1326205 · Engraved from SEC EDGAR
Operating Cash Flowderived-$1,572,000N/M Free Cash Flowderived-$2,448,000N/M Margins · derivedGross margin1.5%−0.7 pt vs Q2 2019
Operating margin-70.7%+34.7 pt vs Q2 2019
Net margin-64.7%+41.2 pt vs Q2 2019
ended Sep 30, 2019 · filed Nov 6, 2019 · 37 d after period end